ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CGEN Compugen Ltd

1.87
-0.04 (-2.09%)
After Hours
Last Updated: 21:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compugen Ltd NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.04 -2.09% 1.87 1.85 1.89 1.94 1.84 1.94 391,563 21:30:00

Compugen to Hold Analyst and Investor Day in New York

27/05/2015 12:00pm

Business Wire


Compugen (NASDAQ:CGEN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Compugen Charts.

A live webcast of the presentations will be available via the Company’s website

Compugen Ltd. (NASDAQ: CGEN) will hold an Analyst and Investor Day in New York on Monday, June 8, 2015, from 9:00 a.m. to 11:00 a.m. ET. A live webcast of the event will be available via the Investors section of Compugen’s website at www.cgen.com. An archived replay of the webcast will be available on the website until July 15, 2015.

Presentations will be presented by members of Compugen’s management team. The event will also feature a presentation by Professor Drew Pardoll, M.D., Ph.D., Professor of Oncology, and Director, Cancer Immunology Program at Johns Hopkins School of Medicine, the Sidney Kimmel Comprehensive Cancer Center. Prof. Pardoll is a member of Compugen’s Scientific Advisory Board.

About Compugen

Compugen is a leading predictive drug discovery company focused on monoclonal antibodies and therapeutic proteins to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of novel drug target candidates, which are then advanced in its Pipeline Program. The discovery and development of monoclonal antibody therapeutic candidates against selected Compugen-discovered novel target candidates is performed by Compugen’s wholly-owned US subsidiary located in South San Francisco. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. For additional information, please visit Compugen's corporate website at www.cgen.com.

Compugen Ltd.Tsipi HaitovskyGlobal Media Liaison+972-52-598-9892tsipih@cgen.com

1 Year Compugen Chart

1 Year Compugen Chart

1 Month Compugen Chart

1 Month Compugen Chart

Your Recent History

Delayed Upgrade Clock